Balanced news tone
News Sentiment
GNLX sentiment intelligence
Genelux Corporation Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
62 relevant articles
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-5.3% over one week, -3.2% over four weeks, trend inactive, and below fair value.
Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
79/100 classification
One-week reaction
-5.3%
Price reacting lower
Trend fit
Trend inactive
-3.2% over four weeks
Fair value
-52.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
13
Neutral
42
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
DirectorsTalk Interviews
Direct company coverage
Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 13 Jul 2026 09:24
- Source
- DirectorsTalk Interviews
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
timothysykes.com
Direct company coverage
Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 04 Jul 2026 07:00
- Source
- timothysykes.com
Stock Titan
Direct company coverage
GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill
GENELUX Corp director John W. Smither sold 12,000 shares of common stock in an open-market transaction at a weighted average price of $2.9082 per share. This sale was made to cover estimated taxes related to the vesting of restricted stock units (RSUs). After the transaction, Smi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:12
- Source
- Stock Titan
TradingView
Direct company coverage
Why Tenet Healthcare (THC) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
Genelux Corporation announced the publication of translational findings from its Phase 1b/2 VIRO-15 trial, demonstrating that Olvi-Vec-primed immunochemotherapy promotes immune activation and chemotherapy sensitization in platinum-resistant/refractory ovarian cancer (PRROC) patie
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 02 Jul 2026 03:40
- Source
- Market source
The Globe and Mail
Direct company coverage
Wall Street Analysts Are Bullish on Top Healthcare Picks
Two Wall Street analysts have issued bullish sentiments on healthcare companies Genelux Corp. (GNLX) and Abivax SA Sponsored ADR (ABVX). Chad Messer of Lake Street maintained a Buy rating on Genelux with a $16.00 price target, while Sam Slutsky of LifeSci Capital maintained a Buy
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 Jul 2026 01:40
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
[144] GENELUX Corp SEC Filing
This article announces a Form 144 SEC filing by GENELUX Corp (GNLX) regarding a proposed sale of 12,000 shares of common stock by an insider. The filing indicates these shares, acquired on June 16, 2026, as restricted stock from the Issuer, have an aggregate market value of $34,8
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 22:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
GENELUX Corp SEC Filing (Jul 1, 2026)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer
Genelux announced the publication of translational and clinical findings from its Phase 1b/2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer. The data indicate that Olvi-Vec modulates the tumor microenvironment, activates immune
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 30 Jun 2026 12:00
- Source
- Stock Titan
TradingView
Direct company coverage
Genelux Corp. Actuals & Estimates (NASDAQ:GNLX)
This article provides an analysis of Genelux Corporation (NASDAQ: GNLX) stock, covering its current price, historical performance, analyst forecasts, and key financial metrics. It includes details on revenue, earnings, market capitalization, and volatility, as well as upcoming ea
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 26 Jun 2026 10:39
- Source
- TradingView
TradingKey
Direct company coverage
Genelux Corp (GNLX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Genelux Corp (GNLX), noting its current valuation score is 6.10, ranking it in the lower range within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.40, which is significantly below its rece
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 24 Jun 2026 22:10
- Source
- TradingKey
TradingKey
Direct company coverage
Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Genelux Corp (GNLX), detailing its current risk score of 1.61, which ranks 281 out of 387 in the Biotechnology & Medical Research industry. The company's beta of 0.54 suggests it tends to underperform during market uptrends but experien
- Tone
- Negative 42/100
- Event
- Analyst action
- Published
- 24 Jun 2026 10:10
- Source
- TradingKey
Investing.com Nigeria
Direct company coverage
Genelux elects director and ratifies auditor at annual shareholder meeting By Investing.com
Genelux Corporation held its 2026 Annual Meeting of Stockholders, where shareholders elected John Smither as a Class I Director and ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The meeting saw
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 22:10
- Source
- Investing.com Nigeria
Investing.com South Africa
Direct company coverage
Form 8K Genelux Corp For: 22 June By Investing.com
This article from Investing.com is a regulatory filing announcement for Genelux Corp, specifically an 8K form filed for June 22. It is a brief notice and does not contain detailed financial information but indicates a significant event or disclosure by the company. The article al
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 22 Jun 2026 21:10
- Source
- Investing.com South Africa
Stock Titan
Direct company coverage
Genelux (GNLX) 2026 meeting backs director John Smither and auditor
Genelux Corporation held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders elected John Smither as a Class I director to serve until the 2029 Annual Meeting. They also ratified Weinberg & Company, P.A. as the independent registered public accounting fir
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:41
- Source
- Stock Titan
TradingKey
Direct company coverage
Genelux Corp (GNLX) Institutional Confidence
Genelux Corp (GNLX) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 14.81% quarter-over-quarter, reaching 30.96%. James Simons is the largest inst
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 19 Jun 2026 07:40
- Source
- TradingKey
TradingKey
Direct company coverage
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Genelux Corp (GNLX), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. As of June 18, 2026, GNLX trades between a resistance of $3.20 and a s
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 19 Jun 2026 07:40
- Source
- TradingKey
Stock Titan
Direct company coverage
GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant
GENELUX Corp's Chief Scientific Officer, Yu Yong, received an equity award of 119,318 restricted stock units (RSUs) at no cash cost under the company’s 2022 Equity Incentive Plan. This grant increases his equivalent common stock position to 269,024 shares, with vesting staggered
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 19 Jun 2026 07:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Genelux (GNLX) director receives RSUs and stock options in new grant
Genelux Corp director Mary Mirabelli was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares of common stock at an exercise price of $3.03. These equity awards increase her direct holdings to 102,693 common shares. Both the RSUs and options vest upon
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Genelux (GNLX) director receives RSU and stock option grants
Genelux (GNLX) director Thomas John was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares with an exercise price of $3.03. These equity awards, not open-market trades, were granted on June 16, 2026, and will vest on the earlier of one year from the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 22:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan
GENELUX Corp's Chief Technical Officer, Joseph Cappello, has been granted 174,841 restricted stock units (RSUs) under the company’s 2022 Equity Incentive Plan. This grant, awarded at no purchase price, increases his total directly held common stock and RSU holdings to 329,390 sha
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 22:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan
Genelux (NASDAQ: GNLX) has granted its President and CEO, Thomas Zindrick, 730,601 restricted stock units (RSUs) under the company’s 2022 Equity Incentive Plan. These RSUs were awarded at no cash cost and will vest 25% on the first anniversary of the grant date, with the remainde
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 22:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants
GENELUX (NASDAQ: GNLX) director James L. Tyree was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares at an exercise price of $3.03. Following these grants, Tyree directly holds 96,483 shares of common stock. Both the RSUs and options will vest on th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 22:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen
Genelux Corp (NASDAQ: GNLX) has granted 233,957 restricted stock units (RSUs) to its General Counsel, Eric Groen, as equity compensation under the company’s 2022 Equity Incentive Plan. These RSUs were awarded at no cash cost and will vest 25% on the first anniversary of the grant
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 22:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
TradingKey
Direct company coverage
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Genelux Corp's (GNLX) dividend and stock split history. It states that Genelux Corp has not distributed any dividends over the past five years and has no recorded stock splits. The financial snapshot shows GNLX's current stock price, market ca
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 07:09
- Source
- TradingKey
TradingKey
Direct company coverage
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Genelux Corp (GNLX), covering business segments, regional revenue, and profit contributions. However, the article states that relevant financial data for these categories have not been disclosed by the compa
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 06:09
- Source
- TradingKey
TradingKey
Direct company coverage
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Genelux Corp (GNLX) has an earnings forecast score of 8.00, placing it highly within the Biotechnology & Medical Research industry. Analysts have set an average price target of $18.00, with a consensus "Buy" rating based on 6 analysts.
- Tone
- Positive 73/100
- Event
- Earnings
- Published
- 17 Jun 2026 06:41
- Source
- TradingKey